{"id":14896,"date":"2023-05-26T07:24:50","date_gmt":"2023-05-26T07:24:50","guid":{"rendered":"https:\/\/jurmed.ro\/medici\/?p=14896"},"modified":"2023-05-26T07:24:50","modified_gmt":"2023-05-26T07:24:50","slug":"cnas-va-putea-compensa-mai-multe-medicamente-noi","status":"publish","type":"post","link":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/","title":{"rendered":"Medicamentele biosimilare &#8211; ce sunt \u0219i cu ce ajut\u0103"},"content":{"rendered":"<p><span style=\"color: #0000ff\"><a style=\"color: #0000ff\" href=\"https:\/\/apmgr.org\/\">APMGR<\/a> <\/span>saluta decizia Casei Nationale de Asigurari de Sanatate (<a href=\"https:\/\/jurmed.ro\/medici\/apmgr-contesta-cresterea-nejustificata-taxei-clawback-si-cere-interventia-corpului-de-control-al-primului-ministru-la-cnas\/\">CNAS<\/a>) si a Ministerului Sanatatii (MS) de a asigura accesul crescut al pacientilor la medicamentele biologice, prin facilitarea accesului la medicamente biosimilare.<\/p>\n<p>Acest lucru se va realiza prin introducerea art. 159 alin. 1-3 din Contractul Cadru (COCA), masura ce va fi implementata incepand cu luna iulie a acestui an.<\/p>\n<p>Aceasta masura poate genera o optimizare bugetara in valoare totala de 27,9 milioane euro in perioada 2023-2026. (IQVIA 2023)<\/p>\n<p>Optimizarea generata de medicamentele biosimilare pe perioada 2023-2027,\u00a0 pentru moleculele care isi pierd exclusivitatea este de 105 milioane euro, 60% din aceasta suma fiind reprezentata de aria terapeutica oncologie.<\/p>\n<p>Conform \u2018\u2019IQVIA\u00a0 Biosimilars competition in Europe 2020\u2019\u2019, pana in anul 2030, aproximativ 100 de molecule biologice isi vor pierde dreptul de exclusivitate, iar o adoptie corecta a medicamentelor biosimilare poate genera optimizari bugetare de 40 miliarde euro la nivel european.<\/p>\n<p>Medicamentele biosimilare au o mare insemnatate strategica pentru guverne, in primul rand pentru ca favorizeaza un acces mai mare al pacientilor la medicamente, precum si pentru ca genereaza optimizare bugetara, cu care CNAS va putea compensa mai multe medicamente noi.<\/p>\n<p>Sustenabilitatea sistemului de sanatate este o provocare pentru multe guverne europene, inclusiv al Romaniei. Imbatranirea populatiei, cresterea incidentei bolilor cronice, cresterea poverii acestor boli, costul ridicat al noilor medicamente pun presiune pe bugetele de sanatate din intreaga Europa.<\/p>\n<p>La 15 ani de la aprobarea primului medicament biosimilar in Europa, s-a ajuns astazi la mai mult de 2 miliarde de zile de tratament cu experienta clinica in deplina siguranta si eficienta.<\/p>\n<p>Mai mult, din momentul in care medicamentele biosimilare au fost disponibile, sistemele de sanatate din tarile membre UE au beneficiat de o optimizare bugetara de 18 miliarde EURO (sursa: The impact of biosimilar competition in Europe, IQVIA, 2021).<\/p>\n<p>Salutam initiativa CNAS si MS, care prin masura propusa in Contractul Cadru art. 159 alin. 1-3, constientizeaza ca Romania trebuie sa profite de aceasta oportunitate pe care medicamentele biosimilare o ofera.<\/p>\n<p>Prin aceasta masura, CNAS solicita atingerea unei cote de 50% medicamente biosimilare din prescrierile pe o anumita molecula, model care se regaseste in multe tari membre UE, ce a generat un acces crescut al pacientilor la terapii valoroase si optimizare bugetara.<\/p>\n<p>De exemplu, Germania a stabilit cote pentru prescrierea medicamentelor biosimilare incepand cu 50% (in functie de land), astfel obtinand pentru molecula adalimumab o optimizare bugetara de peste 1 miliard euro. (Sursa IQVIA)<\/p>\n<p>Un exemplu concludent este pegfilgrastim (utilizat in oncologie), unde in perioada de exclusivitate erau administrate cca 7.000 cicluri de tratament pe an, in vreme ce in prezent sunt administrate anual peste 50.000 cicluri de tratament, preponderent cu medicamente biosimilare cu costuri mai mici.<\/p>\n<p>Astfel, incurajam initiativa CNAS si MS ca fiind solutia de care au nevoie atat pacientii pentru un acces crescut, cat si bugetul pentru compensarea medicamentelor.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>APMGR saluta decizia Casei Nationale de Asigurari de Sanatate (CNAS) si a Ministerului Sanatatii (MS) de a asigura accesul crescut al pacientilor la medicamentele biologice, prin facilitarea accesului la medicamente [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":14897,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[1051,1053,1054,1055,1052],"class_list":["post-14896","post","type-post","status-publish","format-standard","has-post-thumbnail","category-stiri-noutati","tag-apmgr","tag-casa-nationala-de-asigurari-de-sanatate","tag-iqvia","tag-medicamentele-biosimilare","tag-ministerului-sanatatii"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>APMGR saluta decizia CNAS si a Ministerului Sanatatii<\/title>\n<meta name=\"description\" content=\"CNAS solicita atingerea unei cote de 50% medicamente biosimilare din prescrierile pe o anumita molecula\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"APMGR saluta decizia CNAS si a Ministerului Sanatatii\" \/>\n<meta property=\"og:description\" content=\"CNAS solicita atingerea unei cote de 50% medicamente biosimilare din prescrierile pe o anumita molecula\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/\" \/>\n<meta property=\"og:site_name\" content=\"Jurmed - Medici\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-26T07:24:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2023\/05\/download-5.png\" \/>\n\t<meta property=\"og:image:width\" content=\"470\" \/>\n\t<meta property=\"og:image:height\" content=\"207\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"costelv\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"costelv\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/\"},\"author\":{\"name\":\"costelv\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"headline\":\"Medicamentele biosimilare &#8211; ce sunt \u0219i cu ce ajut\u0103\",\"datePublished\":\"2023-05-26T07:24:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/\"},\"wordCount\":456,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2023\/05\/download-5.png\",\"keywords\":[\"APMGR\",\"Casa Nationala de Asigurari de Sanatate\",\"IQVIA\",\"medicamentele biosimilare\",\"Ministerului Sanatatii\"],\"articleSection\":[\"Stiri \/ Noutati\"],\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/\",\"url\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/\",\"name\":\"APMGR saluta decizia CNAS si a Ministerului Sanatatii\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2023\/05\/download-5.png\",\"datePublished\":\"2023-05-26T07:24:50+00:00\",\"author\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"description\":\"CNAS solicita atingerea unei cote de 50% medicamente biosimilare din prescrierile pe o anumita molecula\",\"breadcrumb\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#primaryimage\",\"url\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2023\/05\/download-5.png\",\"contentUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2023\/05\/download-5.png\",\"width\":470,\"height\":207},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/jurmed.ro\/medici\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicamentele biosimilare &#8211; ce sunt \u0219i cu ce ajut\u0103\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\",\"url\":\"https:\/\/jurmed.ro\/medici\/\",\"name\":\"Jurmed - Medici\",\"description\":\"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jurmed.ro\/medici\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\",\"name\":\"costelv\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"caption\":\"costelv\"},\"url\":\"https:\/\/jurmed.ro\/medici\/author\/costelvoicu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"APMGR saluta decizia CNAS si a Ministerului Sanatatii","description":"CNAS solicita atingerea unei cote de 50% medicamente biosimilare din prescrierile pe o anumita molecula","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/","og_locale":"ro_RO","og_type":"article","og_title":"APMGR saluta decizia CNAS si a Ministerului Sanatatii","og_description":"CNAS solicita atingerea unei cote de 50% medicamente biosimilare din prescrierile pe o anumita molecula","og_url":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/","og_site_name":"Jurmed - Medici","article_published_time":"2023-05-26T07:24:50+00:00","og_image":[{"width":470,"height":207,"url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2023\/05\/download-5.png","type":"image\/png"}],"author":"costelv","twitter_misc":{"Scris de":"costelv","Timp estimat pentru citire":"3 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#article","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/"},"author":{"name":"costelv","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"headline":"Medicamentele biosimilare &#8211; ce sunt \u0219i cu ce ajut\u0103","datePublished":"2023-05-26T07:24:50+00:00","mainEntityOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/"},"wordCount":456,"commentCount":0,"image":{"@id":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2023\/05\/download-5.png","keywords":["APMGR","Casa Nationala de Asigurari de Sanatate","IQVIA","medicamentele biosimilare","Ministerului Sanatatii"],"articleSection":["Stiri \/ Noutati"],"inLanguage":"ro-RO","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/","url":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/","name":"APMGR saluta decizia CNAS si a Ministerului Sanatatii","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/#website"},"primaryImageOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#primaryimage"},"image":{"@id":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2023\/05\/download-5.png","datePublished":"2023-05-26T07:24:50+00:00","author":{"@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"description":"CNAS solicita atingerea unei cote de 50% medicamente biosimilare din prescrierile pe o anumita molecula","breadcrumb":{"@id":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/"]}]},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#primaryimage","url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2023\/05\/download-5.png","contentUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2023\/05\/download-5.png","width":470,"height":207},{"@type":"BreadcrumbList","@id":"https:\/\/jurmed.ro\/medici\/cnas-va-putea-compensa-mai-multe-medicamente-noi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/jurmed.ro\/medici\/"},{"@type":"ListItem","position":2,"name":"Medicamentele biosimilare &#8211; ce sunt \u0219i cu ce ajut\u0103"}]},{"@type":"WebSite","@id":"https:\/\/jurmed.ro\/medici\/#website","url":"https:\/\/jurmed.ro\/medici\/","name":"Jurmed - Medici","description":"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jurmed.ro\/medici\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":"Person","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d","name":"costelv","image":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","caption":"costelv"},"url":"https:\/\/jurmed.ro\/medici\/author\/costelvoicu\/"}]}},"_links":{"self":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/14896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/comments?post=14896"}],"version-history":[{"count":1,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/14896\/revisions"}],"predecessor-version":[{"id":14898,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/14896\/revisions\/14898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/media\/14897"}],"wp:attachment":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/media?parent=14896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/categories?post=14896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/tags?post=14896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}